Answers are grounded in this paper and cite their sources.
Study addresses the complexity of penetrance in genetic disorders, highlighting implications for counseling.
Genome scientists are struggling to find the causative DNA variants in more than half of cases of possible genetic disorders which still remain undiagnosed. The struggle to understand if a novel variant is pathogenic or not and to find evidence for interpretation still continue to be challenging. We were aware of incomplete penetrance long before causative genes were identified. Skipped generations in pedigrees of autosomal dominant disorders were good evidence of the existence of this phenomenon in reality. Understanding molecular pathology gave some explanation of decreased penetrance in some disorders, like Fragile X syndrome. Understanding about incomplete penetrance, or the absence of disease phenotype in an individual with the pathogenic DNA variant, is improving, and, in some families, asymptomatic individuals are found to be carriers of the causative variant in the proband. This poses challenges for counseling and prenatal diagnosis. The magnitude of incomplete penetrance was not understood based on the families with affected individuals. But the view appears to be different when population-based databases are explored. A recent study of two huge databases with linked genotype and phenotype data explored manifestations in carriers of pathogenic variants. The population-level penetrance of inherited retinal disorders-associated genotypes was between 9% and 28%, which is markedly lower than prior assumptions of nearly 100%. The GenExpress in this issue presents this and other studies exploring penetrance in population databases to understand the penetrance of “pathogenic” variants. In a study of more than two lac individuals in Geisinger’s MyCode Community Health Initiative, the penetrance for high confidence variants in single disease-associated genes was 15 to 20% only. It means that if genomic sequencing is done for the entire population, detection of cases with subtle phenotypes or early diagnosis may be the advantage, but it also means that interpretation in asymptomatic individuals may be fallacious at this stage when knowledge about genotype-phenotype correlation and modifier genetic variants is very limited. Another study tried to understand causes of lack of manifestations in carriers of loss-of-function variants in gnomAD data in 77 genes associated with severe, early-onset, highly penetrant haplo-insufficient disease. They could identify reasons in 95% of cases. These are large studies beautifully and meticulously crafted to address the magnitude of penetrance in unbiased manner, and the results are worth reading in detail for better understanding of both parties, the laboratories and the clinicians. In other groups of disorders where one gene can cause various phenotypes and a similar phenotype can be caused by more than one gene, the issue may be much more complex. The fourth paper included in GenExpress is a large study to understand molecular genotype-phenotype correlation in ACTB- and ACTG1-related non-muscle actinopathies. In spite of a large number of patients with genotype data and detailed phenotyping, and functional analysis of variants in these genes, not much genotype-phenotype correlation is understood. The study investigators could categorize phenotype groups and felt that clinical classification was useful for accurate diagnosis, management, prognosis, and surveillance. Such large studies are essential as the management is shifting from gene-based strategies to variant-based. More such studies are needed for the progress of personalized medicine. Again, the plan of the study and work done about phenotyping and functional effects is remarkable. Reading the paper is a difficult task, but also a pleasure and good learning for the genomic scientists and clinicians working in the era of molecular medicine. Meticulous collection of genomic and phenotypic data in research mode and mining them for modifiers with the help of artificial intelligence appears to be an important step towards personalized medicine. Offering genome or exome sequencing to an asymptomatic individual without understanding the limitations may lead to overdiagnosis, unnecessary interventions, and may be even undue anxiety. A lot needs to be known about the magnitude and causes of incomplete penetrance, or the absence of disease phenotype in an individual with a disease-associated variant. The problem is huge, especially while evaluating a variant in fetuses where the information about phenotype is absent or very limited. Upscaling of genomics knowledge amongst clinicians is needed to utilize the powerful diagnostic tool with a great responsibility of understanding the limitations and counseling appropriately.
No takes yet. Share an insight, caveat, or question.
Shubha R. Phadke (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: